Latest News for: Covalent

Edit

Initial Quarterly Holdings Report by Institutional Manager (Form 13F-HR) (Covalent Partners LLC)

Public Technologies 17 Feb 2026
) ... The reader should not assume that the information is accurate and complete ... Washington, D.C ... 23.8 ... Covalent Partners LLC ... Covalent Partners LLC published this content on February 17, 2026, and is solely responsible for the information contained herein.
Edit

Covalent Organic Framework (COF) Market to Reach USD 2.79 Billion by 2035, Driven by Advances ...

Nasdaq Globe Newswire 06 Feb 2026
Covalent Organic Framework (COF) Market Size & Segmentation by Type, Linkage Chemistry, Application, End-User, and Region . Global forecast 2026-2035 ... .
Edit

Covalent Expands ISO/IEC 17025 Accreditation to Sixty Metrology Services

Polk County Itemiser-Observer 30 Jan 2026
29, 2026 /PRNewswire/ -- Covalent, a leading provider of ...
Edit

3D covalent organic framework offers sustainable solution for wastewater treatment

Phys Dot Org 30 Jan 2026
To remedy this issue, researchers from Tohoku University developed a three-dimensional covalent organic framework (COF), TU-123, that enables highly efficient and selective removal of anionic dyes from contaminated water.
Edit

Jaypirca® (pirtobrutinib), the First and Only Non-Covalent (Reversible) BTK Inhibitor, Now Available in Canada for ...

Canada Newswire 27 Jan 2026
Jaypirca, a highly selective kinase inhibitor, utilizes a novel binding mechanism and is the first and only approved non-covalent (reversible) BTK inhibitor ... Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies.
Edit

Covalent Metrology Rebrands as Covalent to Reflect Expanded Capabilities and Focus on Material Insights

Missoulian 15 Jan 2026
14, 2026 /PRNewswire/ -- Covalent Metrology today ...
Edit

Frontier Medicines Announces Publication in Nature Communications Highlighting a Novel Method that Enables Next-Generation Covalent Medicines

Nasdaq Globe Newswire 05 Jan 2026
Frontier Medicines Announces Publication in Nature Communications Highlighting a Novel Method that Enables Next-Generation Covalent Medicines ... .
Edit

Dosa: A method to covalently barcode proteins for high-throughput biochemistry

PNAS 02 Jan 2026
.
Edit

Peptide-based covalent inhibitor of tubulin detyrosination promotes mesenchymal-to-epithelial transition in lung cancer cells

PNAS 31 Dec 2025
It involves alteration in expression of ... .
Edit

WCIRDC 2025 COVALENT 111 Week 52 final Oral Presentation (Biomea Fusion Inc)

Public Technologies 08 Dec 2025
) COVALENT-111. Durable Glycemic and C-Peptide Improvements Through Week 52 with Icovamenib, a Menin Inhibitor Targeting Beta-Cell Restoration in Insulin-Deficient Type 2 Diabetes ... CONFIDENTIAL ... COVALENT-111 Trial Design ... COVALENT-111 Trial Design ... N=268.
Edit

Blums, Coval score 16 each off the bench, Davidson knocks off Citadel 79-63

The Joplin Globe 05 Dec 2025
Roberts Blums and Nick Coval came off the bench to score 16 points each to lead Davidson over Citadel 79-63 on Thursday. The Wildcats moved to 7-1 with the win and the Bulldogs fell to 2-7 ... .
Edit

Biomea Fusion Presents COVALENT-111 Study Results at the 23rd World Congress on Insulin Resistance, Diabetes ...

Nasdaq Globe Newswire 05 Dec 2025
Durable Glycemic and C-Peptide Improvements with Icovamenib in Insulin-Deficient Type 2 Diabetes. Durable Glycemic and C-Peptide Improvements with Icovamenib in Insulin-Deficient Type 2 Diabetes ... .
Edit

Biomea Fusion Presents COVALENT-111 Study Results at the 23rd World Congress on Insulin

Caledonian Record 05 Dec 2025
BMEA), a clinical-stage diabetes and obesity company, ...
Edit

WCIRDC 2025 COVALENT 111 Week 52 Poster (Biomea Fusion Inc)

Public Technologies 05 Dec 2025
‌COVALENT-111 ... Icovamenib is an oral, menin inhibitor in clinical development for T2D and T1D COVALENT-111 (Expansion Phase) ... Early COVALENT-111 results showed short-term icovamenib dosing (4-12 weeks) ...
Edit

U.S. FDA approves expanded indication for Lilly's Jaypirca (pirtobrutinib), the first and only non-covalent (reversible) ...

Billings Gazette 04 Dec 2025
Approval is based on results from the BRUIN CLL-321 trial, the only randomized Phase 3 study in CLL/SLL in which all patients were previously treated with a covalent BTK inhibitor ... .

Article Search

tools
×
×
×
×